Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...

With a market valuation of Rs 11,574.76 Cr, Sanofi Indias shares ended Fridays trading session on the BSE 0.58% higher at Rs ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...

KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.

Lung function assessment factoring in race performed poorly in flagging asthma among Black children, a study showed. The 2012 ...

The current rate for a 30-second spot during the 2025 telecast ranges between $1.7 million and $2.3 million, an individual ...

"FIIs still have $800 billion worth of Indian equities. And I believe that will change and increase," Chari added.

Medicare Part D spending for 10 selected diabetes drugs in the USA totaled $35.8 billion in 2023, an increase of 364% from ...

During the week, the BSE Large-cap Index shed 3.4 percent, BSE Mid-cap Index declined 4.4 percent and the BSE Small-cap index ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 11,666.74 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...